Alison Allen, MD
Neurology · Basalt, CONPI 1285780874
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,537 of the $8,551 with a category attached, or 76.5%. It is spread thinly across 43 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,316 and has fallen 73.8% since, to $869 in 2025.
Across 301 payments — averaging $28.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2K
- AbbVie$855
- Novartis$817
- EMD Serono, Inc.$501
- Lilly USA, LLC$384
- Biogen$375
- plus $4K from 37 others
Across 279 payments — averaging $17,267 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.4M
- Novartis$2M
- Amgen$96K
- TG Therapeutics, Inc.$63K
- Genentech, Inc.$60K
- Biogen$58K
- plus $159K from 8 others
What the payments were for
- Speaking & faculty fees$2743%
- Travel & lodging$1,53818%
- Food & beverage$6,53776%
- Education$2012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,551 in reported general payments places this provider in the 75th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $433 |
| Memantine Hcl | 12 | $364 |
| Levetiracetam | 11 | $334 |
Paid to pharmacies, not to this prescriber.
Other neurology in Basalt
- Tamara MillerFort Collins$1.4M
- Justin MoonDenver$1.4M
- Ravi ShahParker$1.3M
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Jeffrey BennettAurora$605K
- Beverly GilderLone Tree$558K
- Michael AmentDenver$457K
- Enrique AlvarezAurora$407K
- Adam WolffDenver$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.